electroCore to Announce Third Quarter September 30, 2024 Financial Results on Wednesday, November 13, 2024
October 23, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Oct. 23, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial...
electroCore to Participate in Upcoming Investor Conferences
September 26, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., Sept. 26, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate...
Big Screen Entertainment Group Launches Big Screen Capital to Fund a Range of New Projects
September 13, 2024 09:33 ET
|
Big Screen Entertainment Group
Big Screen Entertainment Launches Big Screen Capital to Fund Various Start Ups
electroCore Announces the Commercial Launch of TAC-STIM™
June 25, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., June 25, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, is thrilled to announce the Commercial Off the...
electroCore to Join Russell Microcap® Index
June 11, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., June 11, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that its stock is on the...
Amber Therapeutics Closes $100 Million Series A Financing to Advance Breakthrough Amber-UI Neuromodulation Therapy for Mixed Urinary Incontinence towards US FDA Approval
June 10, 2024 03:00 ET
|
Amber Therapeutics
US approval would make Amber-UI the first fully implantable adaptive neuromodulation therapy for women with mixed urinary incontinence (MUI)By targeting the pudendal nerve, Amber-UI has the unique...
electroCore, Inc. Announces Closing of $9.3 Million Registered Direct Offering and Concurrent Private Placements Priced At Market Under Nasdaq Rules
June 06, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., June 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a commercial-stage bioelectronic medicine and wellness company, today announced...
electroCore Announces First Quarter 2024 Financial Results
May 08, 2024 16:05 ET
|
electroCore, Inc.
Record first quarter 2024 net sales of $5.4 million, an increase of 96% over first quarter 2023Company to host a conference call and webcast today, May 8, 2024 at 4:30 PM EST ROCKAWAY, N.J., May 08,...
electroCore Expands Intellectual Property Portfolio
April 02, 2024 08:00 ET
|
electroCore, Inc.
ROCKAWAY, N.J., April 02, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue...
Amber Therapeutics announces positive preliminary results from its first-in-human investigation of Amber-UI, its new adaptive implanted pudendal neuromodulation system for urinary incontinence
February 27, 2024 09:00 ET
|
Amber Therapeutics
Key initial results from AURA-2 study highlight good safety and scalability of Amber-UI therapy A strong efficacy signal was seen in the form of complete resolution of incontinence episodes six months...